Best in Biotech 23 Sep 2025 Navigating German biotech: 14 key players to know The German biotech ecosystem is well established despite the challenges it is facing. Discover thirteen key Germany-based biotech companies. September 23, 2025 - 16 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jan 2025 ITM-11 succeeds in phase 3: The first big win for radiopharma? Discover ITM and its cancer candidate ITM-11, as it brings one of the first big wins the radiopharmaceutical sector awaits. January 28, 2025 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 25 Nov 2024 Evotec on the brink of acquisition: At what cost for the biotech industry? As the signs point toward a potential Evotec acquisition, delve into what it could represent for the European biotech landscape. November 25, 2024 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 15 Oct 2024 Booster launches to treat neurodegenerative diseases with proteasome activation Discover Booster Therapeutics’ novel proteasome activation approach to neurodegenerative diseases as it launches with $15 million. October 15, 2024 - 6 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jul 2024 German biotech raises $150M on its way to tackle cancer therapy resistance On its way to tackle cancer therapy resistance with its monoclonal antibody visugromab, CataLym completes a $150 million series D round. July 16, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Podcast 17 May 2024Isarna Therapeutics revolutionizes ophthalmology with antisense oligonucleotides German-headquartered Isarna Therapeutics is developing a portfolio of antisense therapies targeting an emerging therapeutic field in human biology – transforming growth factor beta (TGF-B) signaling. Precise modulation of TGF-B pathways using antisense therapy may result in safer and more effective treatment options for a broad range of indications. Isarna Therapeutics’s lead compound, ISTH0036, is in […] May 17, 2024 Share WhatsApp Twitter Linkedin Email
Best in Biotech 8 Mar 2024 Eight biotechnology universities in Germany cultivating future leaders Explore Germany’s top biotechnology universities! Uncover where tomorrow’s leaders are trained, bridging science with market success. March 8, 2024 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2023 CatalYm shows importance of GDF-15 in tumor immunotherapy resistance CatalYm has published preclinical data in Nature Communications that reveal the central role of Growth Differentiation Factor-15 (GDF-15) in the resistance of tumors to current immunotherapy. CatalYm said the findings further highlight the therapeutic significance of its proprietary anti-GDF-15 antibody candidate, visugromab, currently in advanced phase 2 clinical studies. The foundational research, which was performed […] July 20, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jul 2023 TME Pharma provides positive glioblastoma trial results TME Pharma N.V. has announced a positive clinical update on the best response to therapy, reporting one patient achieving complete response in the GLORIA expansion arm evaluating NOX-A12, TME Pharma’s CXCL12 inhibitor, in combination with standard of care radiotherapy and anti-VEGF, bevacizumab, in first-line glioblastoma. TME Pharma is a biotechnology company focused on developing novel […] July 14, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jul 2023 TolerogenixX expands trial and closes €12M financing TolerogenixX GmbH, a biopharmaceutical company developing personalized cellular therapies aimed at achieving sustained immune tolerance to combat organ rejection and autoimmune diseases, has announced that its phase IIb study in renal transplant patients has received the green light to initiate the B arm of the study. This arm consists of patients receiving minimal immune suppression […] July 7, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jun 2023 Small particles will deliver TB drugs to the lungs in the future Treatment of the dangerous infectious disease tuberculosis faces the challenge of pathogens frequently being resistant to several common antibiotics. Researchers at Karlsruhe Institute of Technology (KIT) in Germany have developed nanoparticles to deliver new antibiotics directly to the lungs in the future. Surfactants ensure that the highly fat-soluble antibiotics disperse very finely in water and […] June 28, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 May 2023 smartbax raises €1.2M to create next-generation antibiotics smartbax, a biotech company developing next-generation antibiotics against multi-drug resistant bacteria, today announced the close of its seed financing round of €1.2 million ($1.3 million) from Boehringer Ingelheim Venture Fund (BIVF) and High-Tech Gründerfonds (HTGF), bringing smartbax’s total capital raised to €1.9 million ($2.1 million). The funds will be used to advance smartbax’s small molecule […] May 24, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email